Fig. 8: PRKCSH promotes radioresistance and poor prognosis in rectal cancer.
From: PRKCSH enhances colorectal cancer radioresistance via IRE1α/XBP1s-mediated DNA repair
A PRKCSH expression levels in colon adenocarcinoma (COAD) were analyzed using TCGA datasets, comparing normal tissue (n = 349) with colorectal adenocarcinoma tissue (n = 275). B A survival analysis of colorectal cancer patients was conducted based on PRKCSH expression, comparing high (n = 116) and low expression (n = 322) groups. C Representative patient-derived organoid (PDO) images showing tumor growth in NC and PRKCSH-KD groups at Day 1 and Day 3. PRKCSH knockdown validation was performed via Western blot (top). D Quantitative analysis of relative surface area of PDOs on Day 1 and Day 3. E Immunohistochemical (IHC) staining of PRKCSH in rectal cancer tissues, comparing radiosensitive (TRG = 0–1) and radioresistant (TRG = 2–3) tumors, as well as adjacent normal tissues. F Statistical analysis of PRKCSH-positive cell rates in tumors and adjacent normal tissues. G Comparison of PRKCSH-positive cell rates between radiotherapy-sensitive (TRG: 0–1) and resistant (TRG: 2–3) rectal cancer tissues. H PRKCSH was identified as a regulator of colorectal cancer radiosensitivity, promoting DNA damage repair via the IRE1α/XBP1s signaling pathway. Statistical significance is indicated by *P < 0.05, **P < 0.01, ***P < 0.001.
